<DOC>
	<DOCNO>NCT01857895</DOCNO>
	<brief_summary>This open-label study investigate feasibility administer exenatide continuous subcutaneous infusion healthy subject . Study consist two part i.e . Part A B . In Part A 2 healthy subject receive exenatide infusion 24 hour follow follow-up visit 10 14 day discharge clinic . In Part B approximately 6 healthy subject receive subcutaneous infusion exenatide maximum 7 day follow follow-up visit 10 14 day discharge clinic .</brief_summary>
	<brief_title>Feasibility Study Exenatide Continuous Subcutaneous Infusion</brief_title>
	<detailed_description />
	<mesh_term>Exenatide</mesh_term>
	<criteria>Inclusion Criteria Male/females age 18 60 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test 12lead ECG . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator agree document find unlikely introduce additional risk factor interfere study procedure objective . Body Mass Index within range 18 35 kilograms/meter square ( kg/m^2 ) inclusive . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . In questionable case blood sample simultaneous follicle stimulate hormone &gt; 40 milli international unit/mililiter ( mL ) estradiol &lt; 40 picogram/mL ( &lt; 147 picomoles/Liter ) confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . Childbearing potential female must agree use one contraception method . This criterion must follow time first dose study medication follow visit . Capable give write informed consent , include compliance requirement restriction list consent form . Based QT interval correct heart rate ( QTc ) single electrocardiogram ( ECG ) : QTc Fridericia 's formula &lt; 450 millisecond ( msec ) . Aspartate aminotransferase Alanine aminotransferase &lt; 2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin &lt; = 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Exclusion Criteria Subjects personal family history thyroid carcinoma Type 2 Familial Endocrine Neoplasia . History uncorrected thyroid dysfunction abnormal thyroid function assess thyroid stimulating hormone . Subjects history severe gastrointestinal disease , abnormal renal function . Subjects previous exposure Glucagonlike peptide1 mimetic . History chronic acute pancreatitis . Note : Subjects lipase value 1.5X ULN screening exclude . Current chronic history liver disease , hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy . Criteria Based Upon Diagnostic Assessments A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive prestudy drug/alcohol screen . A subject positive urine cotinine test result exclude study unless judgment Investigator subject able abstain use tobacco duration inhouse period study . A positive test human immuno virus antibody . Other Criteria Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Nausea</keyword>
	<keyword>subcutaneous infusion</keyword>
	<keyword>exenatide</keyword>
</DOC>